Take­da turns to emerg­ing mar­kets, West­ern Eu­rope in scram­ble to of­fload Shire debt — re­port

Weighed down by near­ly $50 bil­lion in debt since the Shire deal, Take­da is sell­ing off drugs in emerg­ing mar­kets and West­ern Eu­rope in an ef­fort to get the mas­sive mon­key off their back, Bloomberg re­ports. 

The drugs re­port­ed­ly des­tined for Latin Amer­i­ca, the Mid­dle East, Africa, Rus­sia and Asia, pos­si­bly with­in the next few weeks, come from its 2011 ac­qui­si­tion of Swiss ri­val Ny­comed. In a sep­a­rate deal worth around $1.1 bil­lion, the Japan­ese gi­ant may be­gin sell­ing pre­scrip­tion and over-the-counter drugs in West­ern Eu­rope.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER